Ocugen (2H51) Stock Forecast & Price Target

29 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2H51 Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Ocugen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2H51 Stock 12 Month Forecast

Average Price Target

€8.48

▲(401.50% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is €8.48 with a high forecast of €10.52 and a low forecast of €6.14. The average price target represents a 401.50% change from the last price of €1.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","8":"€8","11":"€11","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.52111988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.47534657,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.13731993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.372,2.0757784523076923,2.7795569046153847,3.483335356923077,4.18711380923077,4.890892261538462,5.5946707138461536,6.298449166153846,7.002227618461538,7.706006070769231,8.409784523076924,9.113562975384616,9.817341427692307,{"y":10.52111988,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.372,1.9184112746153845,2.464822549230769,3.011233823846154,3.5576450984615384,4.104056373076923,4.650467647692307,5.196878922307691,5.743290196923076,6.289701471538461,6.836112746153845,7.38252402076923,7.928935295384614,{"y":8.47534657,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.372,1.7385630715384617,2.105126143076923,2.4716892146153846,2.838252286153846,3.2048153576923077,3.5713784292307693,3.937941500769231,4.3045045723076925,4.671067643846154,5.037630715384616,5.404193786923077,5.770756858461539,{"y":6.13731993,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.796,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.838,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.892,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.359,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.111,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.244,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.203,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.617,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.602,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.372,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€10.52

Average Price Target€8.48

Lowest Price Target€6.14

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Whitney Ijem

Canaccord Genuity

€10.52→€9.64

Buy

470.67%

Upside

Reiterated

05/27/26

Ocugen price target lowered to $11 from $12 at CanaccordOcugen price target lowered to $11 from $12 at Canaccord

Swayampakula Ramakanth

H.C. Wainwright

€8.77

Buy

418.79%

Upside

Reiterated

05/11/26

H.C. Wainwright Keeps Their Buy Rating on Ocugen (OCGN)

Daniil Gataulin

Chardan Capital

€6.14

Buy

263.16%

Upside

Reiterated

05/07/26

Chardan Capital Remains a Buy on Ocugen (OCGN)

Leland Gershell

Oppenheimer

€8.77

Buy

418.79%

Upside

Reiterated

05/06/26

Ocugen (OCGN) Gets a Buy from Oppenheimer

Michael Okunewitch

Maxim Group

€7.01

Buy

315.03%

Upside

Reiterated

05/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), Scholar Rock Holding (NASDAQ: SRRK) and Ocugen (NASDAQ: OCGN)

Robert LeBoyer

Noble Financial

€10.52

Buy

522.55%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Ocugen (NASDAQ: OCGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Solventum Corporation (NYSE: SOLV)

Elemer Piros

Lucid Capital

€13.15→€19.29

Buy

1041.34%

Upside

Reiterated

03/11/26

Ocugen price target raised to $22 from $15 at Lucid CapitalOcugen price target raised to $22 from $15 at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Whitney Ijem

Canaccord Genuity

€10.52→€9.64

Buy

470.67%

Upside

Reiterated

05/27/26

Ocugen price target lowered to $11 from $12 at CanaccordOcugen price target lowered to $11 from $12 at Canaccord

Swayampakula Ramakanth

H.C. Wainwright

€8.77

Buy

418.79%

Upside

Reiterated

05/11/26

H.C. Wainwright Keeps Their Buy Rating on Ocugen (OCGN)

Daniil Gataulin

Chardan Capital

€6.14

Buy

263.16%

Upside

Reiterated

05/07/26

Chardan Capital Remains a Buy on Ocugen (OCGN)

Leland Gershell

Oppenheimer

€8.77

Buy

418.79%

Upside

Reiterated

05/06/26

Ocugen (OCGN) Gets a Buy from Oppenheimer

Michael Okunewitch

Maxim Group

€7.01

Buy

315.03%

Upside

Reiterated

05/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), Scholar Rock Holding (NASDAQ: SRRK) and Ocugen (NASDAQ: OCGN)

Robert LeBoyer

Noble Financial

€10.52

Buy

522.55%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Ocugen (NASDAQ: OCGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Solventum Corporation (NYSE: SOLV)

Elemer Piros

Lucid Capital

€13.15→€19.29

Buy

1041.34%

Upside

Reiterated

03/11/26

Ocugen price target raised to $22 from $15 at Lucid CapitalOcugen price target raised to $22 from $15 at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocugen

3 Months

Michael OkunewitchMaxim Group

Success Rate

7/13 ratings generated profit

Average Return

+6.90%

Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +6.90% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

12/13 ratings generated profit

Average Return

+51.94%

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +51.94% per trade.

2 Years

Michael OkunewitchMaxim Group

Success Rate

12/13 ratings generated profit

Average Return

+51.94%

Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +51.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2H51 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2H51 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2H51 average Analyst price target in the past 3 months is 8.48.

Each month's total comprises the sum of three months' worth of ratings.

2H51 Financial Forecast

2H51 Earnings Forecast

Next quarter’s earnings estimate for 2H51 is -€0.05 with a range of -€0.05 to -€0.04. The previous quarter’s EPS was -€0.05. 2H51 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 2H51 has Performed in-line its overall industry.

2H51 Sales Forecast

Next quarter’s sales forecast for 2H51 is €854.78K with a range of €0.00 to €1.34M. The previous quarter’s sales results were €1.34M. 2H51 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 2H51 has Performed in-line its overall industry.

2H51 Stock Forecast FAQ

What is DE:2H51’s average 12-month price target, according to analysts?

Based on analyst ratings, Ocugen Inc’s 12-month average price target is 8.48.

What is DE:2H51’s upside potential, based on the analysts’ average price target?

Ocugen Inc has 401.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ocugen Inc a Buy, Sell or Hold?

Ocugen Inc has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ocugen Inc’s share price target?

The average share price target for Ocugen Inc is 8.48. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €10.52 ,and the lowest forecast is €6.14. The average share price target represents 401.50% Increase from the current price of €1.69.

What do analysts say about Ocugen Inc?

Ocugen Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Ocugen Inc?

To buy shares of DE:2H51, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ocugen (2H51) Stock Forecast & Price Target

2H51 Analyst Ratings

2H51 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ocugen

2H51 Analyst Recommendation Trends

2H51 Financial Forecast

2H51 Earnings Forecast

2H51 Sales Forecast

2H51 Stock Forecast FAQ

Detailed List of Analyst Forecasts